Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Average Rating of “Moderate Buy” by Brokerages

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has received an average rating of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $57.50.

Several equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Needham & Company LLC reissued a “buy” rating and issued a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, March 20th. Truist Financial set a $58.00 price objective on Collegium Pharmaceutical in a research report on Tuesday, February 10th. Finally, Weiss Ratings lowered Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP David Dieter sold 13,976 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total value of $488,041.92. Following the transaction, the executive vice president directly owned 77,071 shares of the company’s stock, valued at $2,691,319.32. This trade represents a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.85% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Illinois Municipal Retirement Fund raised its position in Collegium Pharmaceutical by 1.6% in the third quarter. Illinois Municipal Retirement Fund now owns 17,281 shares of the specialty pharmaceutical company’s stock valued at $605,000 after purchasing an additional 278 shares during the period. Vident Advisory LLC increased its position in shares of Collegium Pharmaceutical by 1.9% during the third quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock worth $541,000 after acquiring an additional 281 shares during the last quarter. Quadrant Capital Group LLC increased its position in shares of Collegium Pharmaceutical by 4.2% during the fourth quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock worth $324,000 after acquiring an additional 282 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Collegium Pharmaceutical by 9.6% during the fourth quarter. GAMMA Investing LLC now owns 3,262 shares of the specialty pharmaceutical company’s stock worth $151,000 after acquiring an additional 285 shares during the last quarter. Finally, Atom Investors LP increased its position in shares of Collegium Pharmaceutical by 5.0% during the fourth quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock worth $284,000 after acquiring an additional 294 shares during the last quarter.

Collegium Pharmaceutical Trading Up 3.4%

Shares of COLL opened at $34.40 on Wednesday. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. The firm has a market capitalization of $1.12 billion, a P/E ratio of 16.86 and a beta of 0.74. The stock’s fifty day simple moving average is $33.88 and its 200 day simple moving average is $40.72. Collegium Pharmaceutical has a twelve month low of $29.08 and a twelve month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.52 by $0.24. The business had revenue of $193.52 million for the quarter, compared to analyst estimates of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The business’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period last year, the company posted $1.49 EPS. On average, equities research analysts forecast that Collegium Pharmaceutical will post 6.76 earnings per share for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.